These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 22854654)

  • 1. Extended-field intensity-modulated radiotherapy and concurrent cisplatin-based chemotherapy for postoperative cervical cancer with common iliac or para-aortic lymph node metastases: a retrospective review in a single institution.
    Zhang G; Fu C; Zhang Y; Wang J; Qiao N; Yang Q; Cheng Y
    Int J Gynecol Cancer; 2012 Sep; 22(7):1220-5. PubMed ID: 22854654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-dose, prophylactic, extended-field, intensity-modulated radiotherapy plus concurrent weekly cisplatin for patients with stage IB2-IIIB cervical cancer, positive pelvic lymph nodes, and negative para-aortic lymph nodes.
    Liang JA; Chen SW; Hung YC; Yeh LS; Chang WC; Lin WC; Chang YY
    Int J Gynecol Cancer; 2014 Jun; 24(5):901-7. PubMed ID: 23975081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxicity and early clinical outcomes in cervical cancer following extended field helical tomotherapy to para-aortic lymph nodes.
    Jouglar E; Thomas L; de la Rochefordière A; Noël G; Le Blanc-Onfroy M; Delpon G; Campion L; Mahé MA
    Cancer Radiother; 2016 Dec; 20(8):794-800. PubMed ID: 28270323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended-field intensity-modulated radiation therapy combined with concurrent chemotherapy for cervical cancer with para-aortic lymph nodes metastasis.
    Liu X; Wang W; Meng Q; Zhang F; Hu K
    Jpn J Clin Oncol; 2019 Mar; 49(3):263-269. PubMed ID: 30668725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of semiextended field intensity-modulated radiation therapy and concurrent cisplatin in locally advanced cervical cancer patients: An observational study of 10-year experience.
    Lee J; Lin JB; Sun FJ; Chen YJ; Chang CL; Jan YT; Wu MH
    Medicine (Baltimore); 2017 Mar; 96(10):e6158. PubMed ID: 28272204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended field radiotherapy with or without chemotherapy in patients with cervical cancer and positive para-aortic lymph nodes: a single institution retrospective review.
    Ng BH; Rozita A; Adlinda A; Lee WC; Wan Zamaniah W
    Asian Pac J Cancer Prev; 2015; 16(9):3827-33. PubMed ID: 25987044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Treatment of Pelvic Locoregional Recurrence of Cervical Cancer After Radical Surgery With Intensity-Modulated Radiation Therapy Compared With Conventional Radiotherapy: A Retrospective Study.
    Yin YJ; Li HQ; Sheng XG; Du XL; Wang C; Lu CH; Pan CX
    Int J Gynecol Cancer; 2015 Jul; 25(6):1058-65. PubMed ID: 25647254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes for patients with cervical cancer treated with extended-field intensity-modulated radiation therapy and concurrent cisplatin.
    Jensen LG; Hasselle MD; Rose BS; Nath SK; Hasan Y; Scanderbeg DJ; Yashar CM; Mundt AJ; Mell LK
    Int J Gynecol Cancer; 2013 Jan; 23(1):119-25. PubMed ID: 23262521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended field intensity modulated radiation therapy with concomitant boost for lymph node-positive cervical cancer: analysis of regional control and recurrence patterns in the positron emission tomography/computed tomography era.
    Vargo JA; Kim H; Choi S; Sukumvanich P; Olawaiye AB; Kelley JL; Edwards RP; Comerci JT; Beriwal S
    Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1091-8. PubMed ID: 25303889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early clinical outcome with concurrent chemotherapy and extended-field, intensity-modulated radiotherapy for cervical cancer.
    Beriwal S; Gan GN; Heron DE; Selvaraj RN; Kim H; Lalonde R; Kelley JL; Edwards RP
    Int J Radiat Oncol Biol Phys; 2007 May; 68(1):166-71. PubMed ID: 17321070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy.
    Chen CC; Wang L; Lin JC; Jan JS
    J Formos Med Assoc; 2015 Mar; 114(3):231-7. PubMed ID: 25777974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Definitive extended field intensity-modulated radiotherapy and concurrent cisplatin chemosensitization in the treatment of IB2-IIIB cervical cancer.
    Zhang G; He F; Fu C; Zhang Y; Yang Q; Wang J; Cheng Y
    J Gynecol Oncol; 2014 Jan; 25(1):14-21. PubMed ID: 24459576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Surgical Versus Clinical Staging in Chemoradiated FIGO Stage IIB-IVA Cervical Cancer Patients-Acute Toxicity and Treatment Quality of the Uterus-11 Multicenter Phase III Intergroup Trial of the German Radiation Oncology Group and the Gynecologic Cancer Group.
    Marnitz S; Martus P; Köhler C; Stromberger C; Asse E; Mallmann P; Schmidberger H; Affonso Júnior RJ; Nunes JS; Sehouli J; Budach V
    Int J Radiat Oncol Biol Phys; 2016 Feb; 94(2):243-53. PubMed ID: 26853333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment outcomes of extended-field radiation therapy and the effect of concurrent chemotherapy on uterine cervical cancer with para-aortic lymph node metastasis.
    Yoon HI; Cha J; Keum KC; Lee HY; Nam EJ; Kim SW; Kim S; Kim YT; Kim GE; Kim YB
    Radiat Oncol; 2015 Jan; 10():18. PubMed ID: 25582425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcomes of intensity-modulated radiation therapy (IMRT) and high dose rate brachytherapy as adjuvant therapy after radical hysterectomy for cervical cancer.
    Contreras J; Srivastava A; Chundury A; Schwarz JK; Markovina S; Thaker PH; Massad LS; Mutch DG; Powell MA; Grigsby PW; Lin AJ
    Int J Gynecol Cancer; 2020 Aug; 30(8):1157-1161. PubMed ID: 32527770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Definitive extended-field intensity-modulated radiotherapy with chemotherapy for cervical cancer with para-aortic nodal metastasis.
    Jung J; Park G; Kim YS
    Anticancer Res; 2014 Aug; 34(8):4361-6. PubMed ID: 25075072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperfractionated radiotherapy with concurrent chemotherapy for para-aortic lymph node recurrence in carcinoma of the cervix.
    Kim JS; Kim JS; Kim SY; Kim Ki; Cho MJ
    Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1247-53. PubMed ID: 12654434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended field chemoradiation for cervical cancer patients with histologically proven para-aortic lymph node metastases after laparaoscopic lymphadenectomy.
    Marnitz S; Schram J; Budach V; Sackerer I; Vercellino GF; Sehouli J; Köhler C
    Strahlenther Onkol; 2015 May; 191(5):421-8. PubMed ID: 25413986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of failure after use of (18)F-FDG PET/CT in integration of extended-field chemo-IMRT and 3D-brachytherapy plannings for advanced cervical cancers with extensive lymph node metastases.
    Chung YL; Horng CF; Lee PI; Chen FL
    BMC Cancer; 2016 Mar; 16():179. PubMed ID: 26940959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postoperative pelvic intensity-modulated radiotherapy and concurrent chemotherapy in intermediate- and high-risk cervical cancer.
    Folkert MR; Shih KK; Abu-Rustum NR; Jewell E; Kollmeier MA; Makker V; Barakat RR; Alektiar KM
    Gynecol Oncol; 2013 Feb; 128(2):288-93. PubMed ID: 23159818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.